Mon panier

CEACAM-6

CEACAM-6 Informations sur la molécule

Nom anglaisCarcinoembryonic antigen related cell adhesion molecule 6Nombre de médicaments commercialisés0
Nombre de médicaments cliniques3Alias de la cibleCEACAM6,CD66c,NCA,Carcinoembryonic Antigen Related Cell Adhesion Molecule 6,Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6 (Non-Specific Cross Reacting Antigen),Normal Cross-Reacting Antigen,Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6,Non-Specific Crossreacting Antigen,Cluster Of Differentiation 66c,CD66c Antigen,CEAL,CEA Cell Adhesion Molecule 6
Phase de R&D la plus avancéePhase 2 Clinical
Nom anglaisCarcinoembryonic antigen related cell adhesion molecule 6
Alias de la cibleCEACAM6,CD66c,NCA,Carcinoembryonic Antigen Related Cell Adhesion Molecule 6,Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6 (Non-Specific Cross Reacting Antigen),Normal Cross-Reacting Antigen,Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6,Non-Specific Crossreacting Antigen,Cluster Of Differentiation 66c,CD66c Antigen,CEAL,CEA Cell Adhesion Molecule 6
Nombre de médicaments commercialisés0
Nombre de médicaments cliniques3
Phase de R&D la plus avancéePhase 2 Clinical

CEACAM-6 Liste de produits

  • Attribut

    Protein (5)

  • Bibliothèque de produits

    En ligne (5)

  • Espèces

    Human (4)Rhesus macaque (1)

  • Étiquette

    His Tag (2)His Tag & Avi Tag (1)Fc Tag (1)Fc Tag & Avi Tag (1)

  • Marqueur

    Unconjugated (3)Biotin-labeled (2)

CEACAM-6Contexte de la molécule

Carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific cross reacting antigen) (CEACAM6) is also known as CD66c (Cluster of Differentiation 66c), CEAL, NCA, and is one of seven human CEACAM family members within the immunoglobulin superfamily. In humans, CEACAMs include type I transmembrane proteins (CEACAM1, CEACAM3, and CEACAM4) and GPI-linked molecules (CEACAM5 through CEACAM8). There is no human CEACAM2. CEACAM 6 contains one N-terminal V-type Ig-like domain (N domain), followed by two C2-type Ig-like domains. It shows considerable glycosylation, including (sialyl) LewisX, which mediates binding to E-selectin, galectins and some bacterial fimbrae. CEACAM-6 is expressed by granulocytes and their progenitors. It is also expressed by epithelia of various organs and is upregulated in pancreatic and colon adenocarcinomas, as well as hyperplastic polyps. Resistance to adhesion-related apoptosis in tumor cells is conferred in the condition of CEACAM6 overexpression.

CEACAM-6Alias de la molécule

CEACAM6,CD66c,CEAL,NCA

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
NEO-201NEO-201Phase 2 ClinicalNational Cancer Institute, Precision Biologics IncCarcinoma, Non-Small-Cell Lung; Squamous Cell Carcinoma of Head and Neck; Uterine Cervical Neoplasms; Uterine Neoplasms
Details
EBC-129EBC129; EBC-129Phase 1 ClinicalExperimental Drug Development CentreSolid tumours
Details
DNP-002DNP-002Phase 1 ClinicalDinonaSolid tumours
Details
  • Informations sur la molécule
  • Liste de produits
  • Informations sur les médicaments cliniques